Key statistics
As of last trade Immix Biopharma Inc (IMMX:NAQ) traded at 1.85, 5.70% above its 52-week low of 1.75, set on Jun 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.90 |
---|---|
High | 1.95 |
Low | 1.81 |
Bid | 1.83 |
Offer | 1.86 |
Previous close | 1.86 |
Average volume | 79.14k |
---|---|
Shares outstanding | 27.45m |
Free float | 16.42m |
P/E (TTM) | -- |
Market cap | 51.06m USD |
EPS (TTM) | -0.8411 USD |
Data delayed at least 15 minutes, as of Sep 16 2024 20:04 BST.
More ▼
- Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
- California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
- Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
- Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
- Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
- Immix Biopharma on Track to Dose NXC-201 Patients in United States
- Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
- Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
- Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
- Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
More ▼